

Contents

1	Introduction	1
2	Why Now the Need for a New Clinical Trials Model for Antidepressants?	5
3	Reconceptualizing Depression, and the Current Scene on Dimensionality and the RDoC	9
	“Opposed Neurobehavioral States”	11
	On Replacing Diagnosis with Dimensions: The Current Scene and the RDoC	12
4	Aims and Basic Requirements of Clinical Trials: Conventional and Component-Specific Models	13
5	Methods for Measuring the Components and the Profile of Drug Actions: The Multivantaged Approach	17
6	Achieving the “Ideal” Clinical Trial: An Example of Applying the Merged Componential and Established Models	21
	Applying the Models	22
	Measurement of Behavioral Components and Severity of Depressed State	23
7	Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial	27
	Secondary Aims	27
8	Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model	31
9	The Video Clinical Trial	35
	Special Application in Multicenter Trials and Proof-of-Concept Studies . . .	37
10	Conclusions	39

**Appendix I: Four Case Studies of Patients in Multivantage (MV) and
Video Models of Clinical Trials: Instructions for Scoring MV
Components and Dimensions and Video Measure Profiles. . . .** 41

**Appendix II: Operational Definitions of State Constructs
and Global Outcome Measures.** 51

**Appendix III: Composition and Scoring of Constructs,
Dimensions and Overall Severity Measures.** 53

**Appendix IV: MV Methods for Measuring Constructs
and Outcome Dimensions, Brief Version
for Outpatient Studies** 59

References 61

Index. 65

<http://www.springer.com/978-3-319-26463-9>

Clinical Trials of Antidepressants
How Changing the Model Can Uncover New, More
Effective Molecules

Katz, M.M.

2016, XV, 66 p. 3 illus. in color., Softcover

ISBN: 978-3-319-26463-9